TARGETWATCH
BABavarian Nordic
Bavarian Nordic
Aktueller Kurs
180,00 DKK
22.7.2026
Neueste
250,00 DKK
+38.89%
Aufwärtspotenzial
BAVA
3 Mon.+38,89%1 Kursziele
6 Mon.+36,11%5 Kursziele
1 Jahr+35,55%7 Kursziele
Max 7 Kursziele
Nordea
GesundheitswesenBiotechnologie

Über das Unternehmen

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Yahoo Finance

Aktuelles Kursziel

Kursziel
250,00 DKK
Aufwärtspotenzial
+38,89%
Aktueller Kurs180,00 DKK

Weitere Kursziele für Bavarian Nordic

Analyst
Datum
Jul 9
Kursziel
250,00 DKK

Analyst
Datum
Feb 20
Kursziel
139,99 DKK

Datum
Feb 17
Kursziel
280,00 DKK

Analyst
Datum
Feb 3
Kursziel
275,00 DKK

Analyst
Datum
Jan 28
Kursziel
280,00 DKK

Datum
Nov -25
Kursziel
250,00 DKK

Analyst
Datum
Aug -25
Kursziel
233,00 DKK